Zim Laboratories Limited — PPTs, 12-11-2025: Investor Presentation

Zim Laboratories' H1FY26 operating income dipped to 160.5 Cr (down 7.8% YoY), with EBITDA at 13.5 Cr (down 32.2%), leading to a net loss of 2.3 Cr. This was largely due to a critical EU-GMP audit observation impacting European commercialization. However, Q2FY26 showed a sequential rebound, with operating income up 23.6% QoQ to 88.7 Cr and EBITDA rising 36.8% to 7.8 Cr, narrowing its Q2 loss to 0.4 Cr. Pharma contributed 83% of Q2 revenue, growing 30.7% QoQ.

Management is actively addressing the EU-GMP findings with a detailed CAPA remediation plan, including appointing European consultants and strengthening quality systems, aiming for alternate market registrations for 'Star Product 1' by Q1FY27. R&D remains key, with 15.5 Cr invested in H1FY26 to advance innovative product pipelines. Total Capex of 7.2 Cr in H1FY26 focused on BE studies and registrations. The company is exploring contract manufacturing and beefing up its Quality Management System team.